Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
about
Purinergic Signalling: Therapeutic Developments.The D2 Dopamine Receptor Interferes With the Protective Effect of the A2A Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration.Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.Emerging Roles of Nucleoside Transporters.The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease
P2860
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
@en
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
@nl
type
label
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
@en
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
@nl
prefLabel
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
@en
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
@nl
P2093
P2860
P921
P356
P1476
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
@en
P2093
Chiung-Mei Chen
Chun-Jung Lin
Hsing-Lin Lai
Hui-Mei Chen
Yijuang Chern
Yu-Han Kao
P2860
P304
P356
10.1093/HMG/DDW402
P577
2017-01-09T00:00:00Z